CFDE Data Portal | Search PCMTD1-DT

	Label	Description
	PCMTD1-DT Gene (Entity type)	ENSG00000228801 - PCMTD1 divergent transcript
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE163862 2 V 3 CISPLATIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

PCMTD1-DT

ENSG00000228801 - PCMTD1 divergent transcript

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 7 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE163862 2 V 3 CISPLATIN MOUSE DN

A Gene Set from LINCS

GSE146982 metformin 4 v 2 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.